Evaluation of methodology, reporting and transparency of 50 highly cited randomised trials in neurology: a cross-sectional analysis

STRENGTHS AND LIMITATIONS OF THIS STUDY

  • The study followed a standardised approach throughout all steps of this methodological study according to a prospectively registered protocol and study selection, data extraction and assessments were performed independently by two reviewers.

  • Methodological quality, reporting quality and several facets of transparency, including trial registration, results posting, and protocol, analytic code and data availability, were assessed.

  • Risk of bias, completeness of reporting and transparency were assessed using standardised instruments, such as the revised Cochrane risk-of-bias tool (RoB 2) and a checklist based on the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement and its extension for abstracts.

  • The 10 most-cited eligible trials per year from 2018 to 2022 were identified based on citation rank.

  • All assessments were based on publicly accessible sources without contacting trial authors, so that risk-of-bias judgements and evaluation of reporting and transparency reflect…
    This post was originally published on https://bmjopen.bmj.com